Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Can AI Fix Clinical Trial Access in Oncology? Dr. Arturo Loaiza-Bonilla Built the Answer With ...

13 November 2026 · By · Wire by Fusion42

Published

13 November 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 14 November 2026 · Fusion42 review

Dr. Arturo Loaiza-Bonilla co-founded Massive Bio to address inequity in oncology clinical trial access by creating an AI platform that matches patients to trials using electronic medical record data. While the AI increases identification of matches, the main challenge remains patient engagement and enrolment.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You can no longer rely just on AI to find trial matches; the bottleneck is patient sign-up and education. Focus on tools and partnerships that boost engagement to turn AI leads into patients.

◆ Coverage

1 source · 13 Nov 2026

◆ Related on Wire

◆ Topics

Healthoncologyclinical-trialsai-matchinghealthtechpatient-engagement